****When not purchasing directly from the official sales agents of the WHO, especially at online bookshops, please note that there have been issues with counterfeited copies. Buy only from known sellers and if there are quality issues, please contact the seller for a refund.***** Thoracic Tumoursis the fifth available volume in the fifth edition of the WHO series on the classification of human tumours. This series (also known as the WHO Blue Books) is regarded as the gold standard for the diagnosis of tumours and comprises a unique synthesis of histopathological diagnosis with digital and molecular pathology. These authoritative and concise reference books provide indispensable international standards for anyone involved in the care of patients with cancer or in cancer research, underpinning individual patient treatment as well as research into all aspects of cancer causation, prevention, therapy, and education. What's new in this edition? The fifth edition, guided by the WHO Classification of Tumours Editorial Board, establishes a single coherent cancer classification presented across a collection of individual volumes organized on the basis of anatomical site (digestive system, breast, soft tissue and bone, etc.) and structured in a systematic manner, with each tumour type listed within a taxonomic classification: site, category, family (class), type, and subtype. In each volume, the entities are now listed from benign to malignant and are described under an updated set of headings, including histopathology, diagnostic molecular pathology, staging, and easy-to-read essential and desirable diagnostic criteria. Who should read this book? * Pathologists * Oncologists * Respiratory physicians * Thoracic radiologists * Cancer researchers * Surgeons * Epidemiologists * Cancer registrars This volume: * Prepared by 217 authors and editors * Contributors from around the world * More than 1000 high-quality images * More than 3500 references

As with other books in the Molecular Pathology Library Series, Molecular Pathology of Lung Cancer bridges the gap between the molecular specialist and the clinical practitioner, including the surgical pathologist who now has a key role in decisions regarding molecular targeted therapy for lung cancer. Molecular Pathology of Lung Cancer provides the latest information and current insights into the molecular basis for lung cancer, including precursor and preinvasive lesions, molecular diagnosis, molecular targeted therapy, molecular prognosis, molecular radiology and related fields for lung cancer generally and for the specific cell types. As many fundamental concepts about lung cancer have undergone revision in only the past few years, this book will likely be the first to comprehensively cover the new molecular pathology of lung cancer. It provides a foundation in this field for pathologists, medical oncologists, radiation oncologists, thoracic surgeons, thoracic radiologists and their trainees, physician assistants, and nursing staff.

WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart is the seventh volume in the Fourth Edition of the WHO series on histological and genetic typing of human tumors. This authoritative, concise reference book provides an international standard for oncologists and pathologists and will serve as an indispensable guide for use in the design of studies monitoring response to therapy and clinical outcome.

This is the second, completely updated edition of a comprehensive book in which many of the world’s leading lung cancer specialists discuss the recent advances in the radiation oncology of lung cancer and reflect on the latest research findings. The first three sections cover the basic science of lung cancer, clinical investigations, including histology and staging, and a wide range of fundamental treatment considerations. Current treatment strategies for small cell and non-small cell lung cancer are then explained and evaluated in detail, with due attention to novel approaches that promise further improvements in outcome. The various types of treatment-related toxicity are discussed, and quality of life studies and prognostic factors are also considered. After evaluating the latest technological and biological advances, including IMRT, IMAT, cyber knife treatment, and tomotherapy, the book concludes by thorough consideration of specific aspects of clinical research in lung cancer.

Advances in Surgical Pathology: Lung Cancer, a volume in the Advances in Surgical Pathology series, features chapters on current and impending changes in the field of lung cancer that directly affect pathologists. This includes the 2004 updates of the WHO Classification of Tumors of the Lung; the ongoing new classification of neuroendocrine carcinomas of the lung by the International Association for the Study of Lung Cancer; the ongoing revision of the pathologic and clinical staging of lung cancer by the AJCC; molecular diagnostics in the diagnosis of lung cancer; the role of the pathologist in the new molecular targeted therapies for lung cancer; and the new use of image-guided, multimodality theranostics for the diagnosis and treatment of lung cancer. Other current topics discussed include new understanding of the premalignant and preinvasive lesions and the controversies and revisions of the diagnosis of bronchioloalveolar carcinoma.

This book describes the molecular mechanisms of lung cancer development and progression that determine therapeutic interventions in the era of genomics, when the rapid evolution in lung cancer diagnosis and treatment necessitates critical review of new results to integrate advances into practice. The text opens with background and emerging information regarding the molecular biology of lung cancer pathogenesis. Updated results regarding lung cancer prevention and screening are discussed, followed by chapters on diagnostic techniques and pathological evaluation. This leads on to a detailed presentation of treatment modalities, from surgery and radiation therapy to standard chemotherapy and targeted agents. The coverage includes resistance to therapy and the emergence of immunotherapy for lung cancer; in addition, the current evidence in respect of small cell lung cancer is summarized. The book presents insights from experts across disciplines to emphasize the importance of collaborative care. Advances in our understanding of issues in geriatric oncology and palliative care complete the comprehensive discussion of lung cancer.